Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GMP Lapses At Biocon’s Indian Site – Jitters for Neulasta Biosimilar Plans?

Executive Summary

Biocon’s facility in Bangalore, India, has failed to pass muster with the US FDA, raising questions on whether this could result in a pushback of commercialization timelines for partner Mylan’s biosimilar pegfilgrastim in the US. The European regulator has also not cleared the Bangalore site. 

You may also be interested in...



Toujeo, Perjeta Biosimilars On Biocon-Mylan Menu But Humira Version Iffy

Biocon is building on its alliance with Mylan and the partners are adding biosimilar programs for insulin glargine 300 units/mL and pertuzumab to their pipeline. But there's little clarity on the duo's ongoing program for biosimilar adalimumab in the backdrop of Mylan's recent deal with Fujifilm Kyowa Kirin Biologics for its product.

Mylan Poised To Launch Its First US Biosimilar, With A Stacked Pipeline Behind It

A biosimilar of Amgen's Neulasta appears on track for FDA approval by the June 4 action date, management said during an investor briefing that showcased Mylan's expansive biosimilar pipeline. Mid- to late-stage copies of products like Advair, Symbicort, Herceptin, Humira, Avastin, Rituxan, Eylea and Botox highlight the strategic direction Mylan moved in nearly a decade ago. 

How Biocon Site Prevented FDA 'OAI' Finding From Derailing Biosimilars

By carrying out certain corrective and preventive actions, a Biocon facility in Bangalore, India, averted an "official action indicated" finding US FDA officials had proposed in an establishment inspection report, one that could have potentially delayed approval of two Mylan biosimilars. Key issues at the site included visible particles in sterile injectable drug products as well as various aseptic processing practices.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB002383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel